Study of Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Inclusion Criteria

• Have an advanced solid tumor of specific types, such as anal, biliary, neuroendocrine, endometrial, cervical, vulvar, small cell lung, mesothelioma, thyroid, or salivary gland carcinoma.
• Have a tumor that is Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR), especially for colorectal cancer in Chinese participants.
• Have a tumor that has not responded to at least one standard treatment and is Tumor Mutational Burden-High (TMB-H).
• Have experienced tumor growth or intolerance to treatments that usually help.
• Be able to provide a tumor sample for study analysis.
• Have a measurable disease that can be tracked by scans.
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Have a life expectancy of at least 3 months.
• Have adequate organ function as determined by specific tests.
• Female participants of childbearing potential must agree to use effective contraception during the study and for 120 days after the last dose.

Exclusion Criteria

• Currently participating in another study or have used an investigational drug or device within 4 weeks before starting this study.
• Have an immune system deficiency or are taking immunosuppressive drugs within 7 days before starting the study.
• Have an active autoimmune disease requiring treatment in the past 2 years.
• Have received certain cancer treatments within 4 weeks before starting the study and have not recovered from side effects.
• Have another active cancer within the past 2 years, except for certain skin cancers or in situ cancers.
• Have active cancer spread to the brain or spinal cord.
• Have a history of severe lung disease or current lung issues.
• Have an active infection needing treatment.
• Have psychiatric or substance abuse issues that would interfere with the study.
• Are pregnant, breastfeeding, or planning to have children during the study and for 120 days after.
• Have participated in previous pembrolizumab studies or received similar treatments.
• Have a history of HIV, active Hepatitis B or C, or tuberculosis.
• Have received a live vaccine within 30 days before starting the study.
• Have a severe allergy to pembrolizumab or its ingredients.
• Have had a tissue or organ transplant.